ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) issued its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.04), Fidelity Earnings reports.
Shares of EPIX traded up $0.04 during midday trading on Friday, reaching $5.34. 1,234 shares of the stock were exchanged, compared to its average volume of 28,263. The stock’s 50 day simple moving average is $5.60 and its 200 day simple moving average is $4.14. The company has a market cap of $108.59 million, a P/E ratio of -3.79 and a beta of 2.01. ESSA Pharma has a twelve month low of $1.41 and a twelve month high of $6.14.
EPIX has been the topic of several research reports. ValuEngine raised ESSA Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, February 4th. Oppenheimer assumed coverage on ESSA Pharma in a report on Thursday, October 24th. They set an “outperform” rating and a $8.00 price target for the company.
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Featured Article: What is a stock portfolio tracker?
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.